Celgene

This study is testing whether adding an experimental drug called golcadomide to the standard drug rituximab works better than current treatment options for people with follicular lymphoma that has come back or stopped responding to prior therapy. It will involve about 400 adults …

This study is testing a drug called luspatercept in children aged 6 to 18 with beta-thalassemia, a genetic blood disorder. Researchers want to find the safest and most effective dose and see if it can help children who need regular blood transfusions require fewer of them, or hel…

This early-stage trial is testing whether adding one of two new drugs (CC-220 or CC-99282) to standard chemotherapy (R-CHOP) is safe and effective for people with previously untreated aggressive B-cell lymphoma. Researchers will first find the safest dose, then expand testing to …

This study aims to see if a newer oral medication called ozanimod works as well as or better than an existing drug, fingolimod, for children and adolescents with relapsing multiple sclerosis (MS). It will involve about 194 young participants and will compare how well each drug co…

This study is testing whether a new drug called BMS-986365 works better and is safer than current standard treatments for advanced prostate cancer that has spread and no longer responds to hormone-blocking drugs. It will involve about 960 men whose cancer has progressed after ini…

This study aims to understand the long-term safety of the drug luspatercept in people with certain blood disorders. It enrolls about 665 adults who have already participated in other luspatercept trials, either to continue treatment or to be monitored in long-term follow-up. The …

This large study aims to see if a new drug combination works better than the current standard treatment for people with multiple myeloma that has returned or stopped responding to previous therapies. Researchers will compare two different three-drug combinations in 810 patients w…

This study is testing a new combination of two drugs, mezigdomide and elranatamab, for people with multiple myeloma that has come back or stopped responding to previous treatments. The main goals are to find the safest and most effective dose and to see how well the combination w…

This program provides access to a cell therapy called ide-cel for people with multiple myeloma when the specific batch made for them doesn't pass all the standard quality checks for commercial sale. It's for patients who are clinically stable and for whom making a new batch isn't…

This study is testing whether an oral medication called BMS-986368 can safely reduce agitation in people with Alzheimer's disease. About 120 participants with Alzheimer's-related agitation will receive either the drug or a placebo pill for comparison. Researchers will measure cha…

This study is testing whether a new oral medication called BMS-986368 can safely reduce muscle stiffness (spasticity) in people with Multiple Sclerosis. Researchers will compare three different doses of the drug against a placebo pill in about 200 participants. The main goal is t…

This study aims to monitor the long-term health of over 1,500 people who received gene-modified T-cell therapy for cancer in earlier trials. Researchers will track participants for up to 15 years to check for any delayed side effects and see how long the modified cells last in th…

This early-stage study aims to understand how two common medications (itraconazole and rifampin) affect the body's processing of an experimental drug called AR-LDD. The research involves 42 healthy adult male volunteers who will take AR-LDD alone and then with each of the other m…